Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Apple Restores Telegram to App Store After Content Policy Violation 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
CAMBRIDGE, Mass., April 05, 2018 -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, will be participating at the following conferences:
| H.C. Wainwright & Co. Global Life Sciences Conference April 9th at 9:00 a.m. CEST – Monte Carlo, Monaco Leerink Partners’ CNS Day April 18th at 10:00 a.m. EST – New York, NY |
About Wave Life Sciences
Wave Life Sciences is a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases. Our chemistry platform enables the creation of highly specific, well characterized oligonucleotides designed to deliver superior efficacy and safety across multiple therapeutic modalities. Our pipeline is initially focused on neurological disorders and extends across several other therapeutic areas. For more information, please visit www.wavelifesciences.com.
Investor Contact:
Jillian Connell
617-949-2981
[email protected]
Media Contact:
Jose Juves
617-949-4708
[email protected]
